"A total of 242 patients have been treated with TLX591 across eight Phase I and Phase II trials9 including a previously published Phase II (open-label, single-arm) trial, which reported a 42.3 month OS in 17 patients with advanced mCRPC when TLX591 was delivered under a fractionated dosing regimen"
I'm not all that deeply researched on TLX but this seems to be their evidence? In a trial of just 17 patients out of 242 total in other trials, I wonder what the OS was for the other 225 patients? Particularly given ""The study has reported a median rPFS of 8.8 months"" in the only trial TLX have actually run
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)